Drug Profile

CVSI 007

Alternative Names: Cannabidiol - CV Sciences; CVSI-007

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CanX
Developer CV Sciences
Class Analgesics; Cannabinoids; Small molecules
Mechanism of Action Cannabinoid receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Smoking withdrawal

Most Recent Events

28 Mar 2025 No recent reports of development identified for preclinical development in Smoking-withdrawal in USA (PO, Gum)
23 Mar 2023 Preclinical development is still ongoing in USA (CV Sciences website, March 2023)
23 Mar 2023 CVSI 007 is available for licensing as of 23 Mar 2023. https://www.cvsciences.com/# 9384786

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com